Lovastatin Tablet
Product Images NDC 72162-1739

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 72162-1739). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621739)

Lovastatin Tablets, USP 10 mg oral tablets packaging label. The label shows NDC 72162-1739 and is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA. The package contains 1000 tablets. Storage instructions and child-resistant container information are provided. Barcodes and lot/expiration details are included.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure diagram showing the molecular arrangement of the active ingredient lovastatin.*

FDA Label Image

Table I (Lov00 0004 02)

A table showing the effect of other drugs on lovastatin exposure when co-administered. It lists drugs and grapefruit juice with corresponding number of subjects, dosing regimens for coadministered drugs, lovastatin dosages, and AUC ratio comparisons of lovastatin exposure with and without coadministration.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' showing the proportion of participants without event over up to 6 years of follow-up. It compares Lovastatin versus placebo, indicating a 37% risk reduction with Lovastatin (p<0.001). The x-axis represents years of follow-up and the y-axis shows the proportion of participants without event.*

FDA Label Image

Table Vii (Lov00 0005 04)

A data table titled 'Table VII Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis' listing interacting agents with lovastatin. It includes categories such as strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin), HIV protease inhibitors, gemfibrozil, cyclosporine, and others, with corresponding prescribing recommendations like contraindications, avoidance, or dosage limits.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.